Drugs / CLR457
last change Nov 2015 re-read 3 minutes ago

CLR457

Developed for
neoplasm
Investigated by
Novartis Pharmaceuticals

Trials 1

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02189174 Aug 2014 → Nov 2015 neoplasm Novartis Pharmaceuticals Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CLR457 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02189174 ↗
Route Oral “Administered Orally” NCT02189174 ↗